ROIVRoivant Sciences Ltd.
$35.42+136% 1Y
$35.42
$14.7052 weeks$41.81
The financials
Roivant Sciences Ltd. by the numbers
Roivant Sciences Ltd. (ROIV) reported revenue of $1.4M in Q1 2026 (quarter ended Jun 30, 2026), down 34% from the same quarter a year earlier. That came with net loss of $190M. For the full year FY2025, revenue was $8.3M (−72% year on year) and net income −$300M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $1.4M | $2.2M | −34% |
| Operating income | −$366M | −$285M | n/a |
| Net income | −$190M | −$223M | n/a |
| Diluted EPS | −$0.26 | −$0.33 | n/a |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.4M (-43%)
Reportable grew -34% year on year
Segment Latestquarter on quarteryear on year
- Reportable$1.4M$1.4Mquarter on quarter -43%year on year -34%-43%-34%
Biotechnology
Ranks #19 of 196 by RyuScore